1. Volume 371, Issue 9626, Pages 1753-1760 (May 2008)
Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial 
Prof Jianping Weng, MD, Prof Yanbing Li, MD, Wen Xu, MD, Prof Lixin Shi, MD, Qiao Zhang, MD, Prof Dalong Zhu, MD, Yun Hu, MD, Prof Zhiguang Zhou, MD, Xiang Yan, MD, Prof Haoming Tian, MD, Xingwu Ran, MD, Prof Zuojie Luo, MD, Jing Xian, MD, Prof Li Yan, MD, Fangping Li, MD, Longyi Zeng, MD, Yanming Chen, MD, Prof Liyong Yang, MD, Sunjie Yan, MD, Juan Liu, MD, Ming Li, MD, Prof Zuzhi Fu, MD, Prof Hua Cheng, MD 
The Lancet 
Volume 371, Issue 9626, Pages (May 2008)
DOI: /S (08)60762-X
Copyright © 2008 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
CSII=continuous subcutaneous insulin infusion. MDI=multiple daily insulin injections. OHA=oral hypoglycaemic agents.
The Lancet  , DOI: ( /S (08)60762-X)
Copyright © 2008 Elsevier Ltd Terms and Conditions

3. Figure 2 Kaplan-Meier estimates of time to primary endpoint
The Lancet  , DOI: ( /S (08)60762-X)
Copyright © 2008 Elsevier Ltd Terms and Conditions

4. Figure 3
Acute insulin response (shown as median) before and after different interventions and at 1 year
*p<0·05 in the non-remission group compared with that in each intervention in the remission group (after treatment).
The Lancet  , DOI: ( /S (08)60762-X)
Copyright © 2008 Elsevier Ltd Terms and Conditions